再生型医用植入器械
Search documents
冠昊生物涨2.04%,成交额1.60亿元,主力资金净流出1364.39万元
Xin Lang Cai Jing· 2026-01-08 02:39
1月8日,冠昊生物盘中上涨2.04%,截至10:22,报17.01元/股,成交1.60亿元,换手率3.61%,总市值 45.10亿元。 冠昊生物今年以来股价涨22.82%,近5个交易日涨22.37%,近20日涨17.80%,近60日涨13.86%。 责任编辑:小浪快报 资料显示,冠昊生物科技股份有限公司位于广东省广州市黄埔区玉岩路12号,成立日期1999年10月22 日,上市日期2011年7月6日,公司主营业务涉及再生医学材料及再生型医用植入器械研发、生产和销 售,以及细胞治疗技术研发、制备、临床应用,免疫细胞存储等。主营业务收入构成为:医疗器械 73.28%,药品15.21%,租赁及其他服务业11.51%。 分红方面,冠昊生物A股上市后累计派现8665.95万元。近三年,累计派现0.00元。 资金流向方面,主力资金净流出1364.39万元,特大单买入232.44万元,占比1.45%,卖出371.44万元, 占比2.32%;大单买入2004.73万元,占比12.51%,卖出3230.12万元,占比20.16%。 机构持仓方面,截止2025年9月30日,冠昊生物十大流通股东中,医疗器械ETF(159883)位居 ...
冠昊生物涨2.27%,成交额944.49万元,主力资金净流入85.67万元
Xin Lang Zheng Quan· 2025-11-24 01:48
Core Viewpoint - Guanhao Biological has shown a mixed performance in stock price, with a year-to-date increase of 23.26% but a recent decline over the past five, twenty, and sixty days [1][2]. Company Overview - Guanhao Biological Technology Co., Ltd. was established on October 22, 1999, and listed on July 6, 2011. The company is located in Huangpu District, Guangzhou, Guangdong Province [1]. - The main business involves research, production, and sales of regenerative medical materials and implantable medical devices, as well as cell therapy technology development, preparation, clinical application, and immune cell storage [1]. - The revenue composition is as follows: medical devices 73.28%, pharmaceuticals 15.21%, and leasing and other services 11.51% [1]. Financial Performance - For the period from January to September 2025, Guanhao Biological achieved an operating income of 293 million yuan, representing a year-on-year growth of 5.52%. However, the net profit attributable to the parent company was 26.72 million yuan, a decrease of 4.02% year-on-year [2]. - The company has cumulatively distributed 86.66 million yuan since its A-share listing, with no distributions in the past three years [3]. Shareholder Information - As of November 10, 2025, the number of shareholders for Guanhao Biological was 29,600, an increase of 4.20% from the previous period. The average circulating shares per person decreased by 4.03% to 8,951 shares [2]. - The top ten circulating shareholders include a new entrant, the Medical Device ETF (159883), holding 1.31 million shares [3]. Market Activity - On November 24, the stock price increased by 2.27% to 14.84 yuan per share, with a trading volume of 9.44 million yuan and a turnover rate of 0.24%. The total market capitalization is 3.935 billion yuan [1]. - The net inflow of main funds was 856,700 yuan, with large orders accounting for 11.99% of total purchases [1].